Needham & Company analyst Mike Matson reiterated a Strong Buy rating and boosted his price target on MiMedx Group (NASDAQ: MDXG) to $15.00 (from $13.00) following Q4 results.

Matson commented, "MDXG's 4Q14 revenue was consistent with its 1/12/15 preannouncement while EPS met consensus. Management maintained its previously updated 2015 guidance and its previously issued 1Q15 guidance. MDXG continues to gain significant market share in its Wound Care business while its Surgical, Sports Medicine, & OEM business saw slower revenue growth. MDXG continued to drive significant margin expansion at both the gross margin and operating margin lines. We believe that the 4Q14 results, guidance reiteration, and management commentary should go a long way to easing concerns about the pass-through and OIG subpoena. We have raised our price target to $15 and reiterate our Strong Buy rating"

For an analyst ratings summary and ratings history on MiMedx Group click here. For more ratings news on MiMedx Group click here.

Shares of MiMedx Group closed at $10.48 yesterday.